The Clearity Foundation, a site dedicated to ovarian cancer research, has reported on a new finding for treating drug resistance in women with BRCA mutations.
Researchers at Washington University School of Medicine in St. Louis have discovered several parallel genes that cause resistance to PARP inhibitors for these women.
PARP inhibitors have been shown to be effective initially but then lose their effectiveness. By targeting these parallel genes, researchers have found a way to make these tumor cells respond to PARP inhibitors again. To read more about this, follow this link.